HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Inclusion Criteria: 1. Voluntarily signed the informed consent form (ICF); 2. Males or females aged 18 to 75 years; 3. Patients diagnosed with primary wAIHA or secondary wAIHA whose underlying diseases are stable; 4. Organs in good function. Exclusion Criteria: 1. Patients with other types of AIHA other than wAIHA; 2. Patients with secondary wAIHA with unstable underlying disease; 3. Patients with drug-induced secondary wAIHA; 4. Patients with infections requiring systemic treatment; 5. Patients previously treated with Syk inhibitors (e.g., fostamatinib); 6. Patients with known allergy to the active ingredients or excipients of the study drug; 7. Patients with serious psychological or mental disorder; 8. Alcoholic or drug abuser; 9. Female patients who are pregnant and lactating.